2024-02-08 07:41:00 ET
Summary
- WuXi AppTec, which could be banned from doing business with federal agencies under proposed legislation, derived 65% of its revenue from the U.S. in the first half of last year.
- The provider of outsourced services to drug makers said it has never sponsored Chinese military projects or received any direct military investment.
- Demand for WuXi AppTec’s services is likely to remain strong, since drug development is still a fast-advancing field.
Proposed U.S. legislation could ban federal agencies and federally funded institutions from buying devices and services from Chinese biotech companies. ...
Read the full article on Seeking Alpha
For further details see:
Potential U.S. Targeting Casts Shadow Over WuXi AppTec Family